What side effects are associated with this type of intervention?

Common treatments for cervical cancer, including targeted therapies and antibody-drug conjugates like SGN-ALPV, often have side effects such as fatigue, nausea, vomiting, diarrhea, and decreased appetite. Additionally, patients may experience hematologic toxicities like anemia, neutropenia, and thrombocytopenia. Skin reactions, including rash and pruritus, are also common. For treatments involving radiation therapy, side effects can include localized pain, skin irritation, and potential damage to surrounding tissues. It's important for patients to discuss these potential side effects with their healthcare provider to manage and mitigate them effectively.

What prior FDA approvals exist?

The FDA has approved several targeted therapies and antibody-drug conjugates for the treatment of cervical cancer. Notably, pembrolizumab, an immune checkpoint inhibitor targeting PD-1, has been approved for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Additionally, bevacizumab, an anti-angiogenic agent, is approved in combination with chemotherapy for persistent, recurrent, or metastatic cervical cancer. These treatments represent significant advancements in targeted therapy for cervical cancer, similar to the investigational approach of SGN-ALPV.

What other types of research exist?

Promising novel alternatives to SGN-ALPV for cervical cancer patients include: 1) Pembrolizumab (Keytruda), an immune checkpoint inhibitor that has shown efficacy in PD-L1 positive cervical cancer. 2) Tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, which has demonstrated promising results in clinical trials. 3) Bevacizumab (Avastin), an anti-angiogenic agent, often used in combination with chemotherapy for advanced cervical cancer. These therapies represent some of the latest advancements in the treatment of cervical cancer.

← Back to Search

Virus Therapy

SGN-ALPV for Cancer

Phase 1

Waitlist Available

Research Sponsored by Seagen Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up approximately 2 years

Awards & highlights

Summary

This trial is testing a new drug called SGN-ALPV in patients with advanced solid tumors. It aims to find the right dosage and see if the drug is safe and effective.

Who is the study for?

This trial is for adults with advanced solid tumors like stomach, cervical, testicular cancers and more. These tumors must be metastatic or unresectable. Participants need confirmed diagnoses and may require biopsies. They should not have had certain recent cancers or treatments that could interfere with the study.

What is being tested?

SGN-ALPV is being tested to determine its safety and effectiveness in treating various solid tumor cancers. The trial has three parts: Parts A and B will establish the proper dose; Part C will assess how safe it is at that dose and if it helps treat cancer.

What are the potential side effects?

While specific side effects of SGN-ALPV are not listed, they can include any unintended effect on your body besides treating the disease. This might involve reactions at the drug injection site, general discomforts like nausea or fatigue, or other organ-specific issues.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ approximately 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~approximately 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of participants with adverse events (AEs)

Secondary study objectives

Apparent terminal half-life (t1/2)

Area under the concentration-time curve (AUC)

CA-125 response rate according to Gynecological Cancer Intergroup (GCIG) criteria (subjects with ovarian cancer only)

+8 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: SGN-ALPVExperimental Treatment1 Intervention

SGN-ALPV monotherapy

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for cervical cancer include surgery, radiation therapy, chemotherapy, and targeted therapies. Targeted therapies, such as those similar to SGN-ALPV, work by interfering with specific molecules involved in cancer growth and progression. For example, antibody-drug conjugates combine an antibody that targets cancer cells with a cytotoxic drug, delivering the drug directly to the cancer cells and minimizing damage to normal cells. This targeted approach is particularly important for cervical cancer patients as it can reduce side effects and improve the effectiveness of the treatment.

Find a Location

Who is running the clinical trial?

Seagen Inc.Lead Sponsor

210 Previous Clinical Trials

74,677 Total Patients Enrolled

3 Trials studying Endometrial Cancer

233 Patients Enrolled for Endometrial Cancer

Suzanne McGoldrick, MDStudy DirectorSeagen Inc.

1 Previous Clinical Trials

111 Total Patients Enrolled

Media Library

SGN-ALPV (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05229900 — Phase 1

Endometrial Cancer Research Study Groups: SGN-ALPV

Endometrial Cancer Clinical Trial 2023: SGN-ALPV Highlights & Side Effects. Trial Name: NCT05229900 — Phase 1

SGN-ALPV (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05229900 — Phase 1

~13 spots leftby Sep 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.